# Urban Endocrine Disruptors Targeting Breast Cancer Proteins

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

# Urban Endocrine Disruptors Targeting Breast Cancer Proteins

*Diana Montes-Grajales [†, ‡], Gonçalo J. L. Bernardes* [†, §] and Jesus Olivero-Verbel* [‡].*

[†]Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, United Kingdom, [‡]Computational Chemistry Group, Faculty of Pharmaceutical Sciences, University of Cartagena, Campus of Zaragocilla, Cartagena, 130015, Colombia, and [§]Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.

KEYWORDS: Endocrine disrupting chemical, BPA, breast cancer, circular dichroism, high-throughput virtual screening.

ABSTRACT: Humans are exposed to a huge amount of environmental pollutants called endocrine disrupting chemicals (EDCs). These molecules interfere with the homeostasis of the body, usually through mimicking natural hormones leading to activation or blocking their receptors. Many of these compounds have been associated to a broad range of diseases including the development or increased susceptibility to breast cancer, the most prevalent cancer in woman worldwide, according to the World Health Organization. Thus, this article presents a virtual

high-throughput screening (vHTS) to evaluate the affinity of proteins related to breast cancer,

such as ESR1, ERBB2, PGR, BCRA1 and SHBG, among others, with EDCs from urban sources.

A blind docking strategy was employed to screen each protein-ligand pair by triplicate in

AutoDock Vina 2.0, using the computed binding affinities as ranking criteria. The three-

dimensional structures were previously obtained from EDCs DataBank and Protein Data Bank,

prepared and optimized by SYBYL X-2.0. Some of the chemicals that exhibited the best affinity

scores for breast cancer proteins in each category were 1,3,7,8-tetrachlorodibenzo-p-dioxin,

bisphenol A derivatives, perfluorooctane sulfonic acid and benzo(a)pyrene, for catalase, several

proteins, sex hormone-binding globulin and cytochrome P450 1A2, respectively. An

experimental validation of this approach was performed with a complex that gave a moderate

binding affinity *in silico*, the sex hormone binding globulin (SHBG) and bisphenol-A (BPA)

complex. The protein was obtained using DNA recombinant technology and the physical

interaction with BPA assessed through spectroscopic techniques. BPA binds on the recombinant

SHBG, and this results in an increase of its alpha helix content. In short, this work shows the

potential of several EDCs to bind breast cancer associated proteins, as a tool to prioritize

compounds to perform *in vitro* analysis to benefit the regulation or exposure prevention by the

general population.

## 1. INTRODUCTION

Endocrine disrupting chemicals (EDCs) are a broad range of molecules with potential to affect

the endocrine system through different ways, metabolic, epigenetic and DNA damage[1b-e]. These

chemicals were classified for first time in the 90's and were defined by the Environmental

Protection Agency (EPA) as substances with the ability to interfere with the synthesis, secretion,

transport, binding, action, or elimination of natural hormones in the body that are responsible for

the maintenance of homeostasis, reproduction, development, and/or behavior[2]. Currently, EPA estimates there exist approximately 10,000 EDCs among the common daily exposures that could impose any risk of disease[3]. Some critical points in the debate around these compounds include the potential to affect the health of humans and wildlife, as well as their progeny[4]; the massive volume of production of some of them and the chronic exposure to the general population through the environment and everyday products[5]. These points have enhanced the scientific concern regarding the safety of these chemicals in recent years.

The exposure to EDCs induces adverse effects, specially related to reproduction, development and different cancer types[6], including breast cancer[7] , which according to the World Health Organization (WHO) is the most common cancer in women, both in the developed and less developed world, estimating that worldwide over 508,000 women died in 2011 due to this disease (http://www.who.int/cancer/detection/breastcancer/en/index1.html). The classic hallmark mechanism in breast cancer is the activation of estrogen receptor, for that reason the responses due to EDCs exposures have been mainly explored and attributed to this signaling pathway[1a]. In general, the understanding on the underlying mechanisms of breast cancer[8] are limited because of its complexity and heterogeneity; nevertheless, there are some proteins recognized as important in its initiation and progression, specially hormone receptors such as estrogen receptor (ESR1), progesterone receptor (PGR), and other proteins, in particular, the human epidermal growth factor receptor 2 (HER-2), breast cancer type 1 susceptibility protein (BRCA1) and breast cancer type 2 susceptibility protein (BRCA2)[9].

Currently, thousands of environmental chemicals are subject to regulatory review for their

potential as EDCs, and *in vitro* high-throughput screening (HTS) assays have emerged as a

potential tool for prioritizing chemicals for whole animal tests[10]. However, computational

toxicology approaches are needed to help to prioritize chemicals for screening[11], focusing on

their interaction with critical disease pathways[12]. In this work we evaluated *in silico* the potential

of EDCs to target breast cancer proteins, using a virtual high-throughput screening (vHTS) and

an *in vitro* validation through spectroscopic methods for one of the predicted protein/ligand

complexes.

## 2.  RESULTS

### 2.1.Text mining

Based on the data mining performed on FABLE, 294 genes/proteins were found to be related

to breast cancer (≥100 citations in PubMed) (Suppl. Table 1), and a total of 133 were suitable for

docking studies and employed for further analysis. This selection was complemented adding

proteins recently discovered as important in breast cancer, as well as with nuclear receptors and

cell cycle regulation proteins. Finally, a total of 189 proteins were selected for the vHTS with

EDCs.

### 2.2.High-throughput virtual screening

A total of 305 EDCs were docked with the proteins related to breast cancer selected in the

previous step. The EDCs were classified according to the potential sources of exposures in four

groups: dioxins and related molecules, plastics and other types of polymers, everyday products

and miscellaneous. Results were ranked according to the affinity scores obtained in AutoDock

Vina[13]. Clustered heat maps of the affinity scores of EDCs against breast cancer proteins are presented for each category as supplementary material (Suppl. Figures 1-4).

The virtual screening allowed the identification of protein-ligand pairs with high affinity, candidates to be tested *in vitro* and *in vivo* for breast cancer in further studies. In the following sections the results in each group of EDCs, according to the exposure source, are presented.

### 2.3.Dioxins and related molecules

The main cluster in the heat map of the virtual screening of breast cancer proteins with dioxins and related molecules (Suppl. Figure 1 and Suppl. Table 2) indicates that these interact mostly with a group of proteins, including catalase (CAT); retinoic acid receptor beta (RARB); SHBG; PGR; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA); nuclear receptor ROR-gamma (RORC); nuclear receptor ROR-alpha (RORA); adiponectin (ADIPOQ); cytochrome P450 3A4 (CYP3A4); phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG) and apolipoprotein D (APOD). Therefore, the underlying mechanisms by which these EDCs elicit their effects could be associated to signaling pathways involved in cell proliferation and oxidative stress, among others.

The complexes that presented the highest affinity score in this group are CAT/1,3,7,8-tetrachlorodibenzo-p-dioxin (Figure 1), and 2,3,4,7-tetrachlorodibenzofuran with the protein cytochrome P450 1A2 (CYP1A2, Figure 2). The top ranking of the complexes formed by EDCs in this group with breast cancer proteins is showed in Table 1.

**Figure 1.** Three-dimensional view of the (A) CAT/1,3,7,8-tetrachlorodibenzo-p-dioxin, (B) showing the binding site and interactions predicted by LigandScout 3.1.



**Figure 2.** Three-dimensional view of the (A) CYP1A2/2,3,4,7-tetrachlorodibenzofuran, (B) showing the binding site and interactions predicted by LigandScout 3.1. The blue arrows represent aromatic ring interactions.

**Table 1.** Dioxins and related molecules with best affinity scores (<-10.0 kcal/mol) after docking with breast cancer associated proteins.

| Short name | PDB | EDCs | CID | Affinity (kcal/mol) |
|---|---|---|---|---|
| CAT | 1DGF | 1,3,7,8-tetrachlorodibenzo-p-dioxin | 149104 | -10.3 |
| CYP1A2 | 2HI4 | 2,3,4,7-tetrachlorodibenzofuran | 55111 | -10.2 |

## 2.4.Plastics and other types of polymers

The docking simulation showed that several EDCs in this category have the potential to bind breast cancer proteins (Suppl. Table 3 and Suppl. Figure 2). However, the derivatives of the well-known plasticizer BPA presented the best affinities, being located the top of the ranking table (Table 2).

**Table 2.** EDCs in plastics and other types of polymers with best affinity scores (<-10.0 kcal/mol) after docking with breast cancer associated proteins.

| Short name | PDB | EDCs | CID | Affinity (kcal/mol) |
|---|---|---|---|---|
| SRC | 2H8H | bisphenol M | 3292100 | -10.8 |
| ESRRG | 2E2R | bisphenol AF | 73864 | -10.8 |
| RXRB | 1H9U | bisphenol M | 3292100 | -10.7 |
| VDR | 1IE9 | bisphenol A dimethacrylate | 76739 | -10.3 |
| VDR | 1IE9 | bisphenol M | 3292100 | -10.3 |
| SHBG | 1F5F | bisphenol M | 3292100 | -10.3 |
| RARB | 4DM6 | bisphenol M | 3292100 | -10.2 |

| ESRRG | 2E2R | bisphenol B | 66166 | -10.2 |
|-------|------|-------------|-------|-------|
| CYP1A2 | 2HI4 | dihydroxymethoxychlor olefin | 84677 | -10.1 |
| HBA1 | 1A01 | 2,4,6-triphenyl-1-hexene | 45356241 | -10.1 |
| CYP1A2 | 2HI4 | diphenyl-p-phenylenediamine | 6319 | -10.1 |

The chemical structures of  BPA and its analogs are presented in Figure 3, as well as their potential targets in breast cancer according to the vHTS, and a functional protein association network generated by STRING[14].

**Figure 3.** A) Chemical structure of BPA and B) its analogs showing the interactions with breast cancer proteins according to docking studies, and the analysis of the protein-protein interactions by STRING v.10[14].

The two complexes with the best affinity score were proto-oncogene tyrosine-protein kinase

Src (SRC)/bisphenol M and estrogen-related receptor gamma (ESRRG)/ bisphenol AF (-10.8

kcal/mol). This is an interesting finding, as bisphenol AF (BPAF), is considered a new bisphenol

analogue used as raw material in plastic industry; however, little is known about its occurrence in

the environment and the potential associated risk[15]. The three-dimensional view of these

complexes and their interactions are presented in Figures 4-5. Most of the interactions were

hydrophobic in nature; however there are some hydrogen bond donor features that suggest the

presence of hydrogen bonds between the ligand and the surrounding residues.



**Figure 4.** Three-dimensional view of the (A) SRC/bisphenol M complex, (B) showing the
binding site and interactions predicted by LigandScout 3.1. The green arrows represent hydrogen-bond donor
features.

**Figure 5.** Three-dimensional view of the (A) ESRRG/bisphenol AF complex, (B) showing the binding site and interactions predicted by LigandScout 3.1. The green arrows represent hydrogen-bond donor features.

**Everyday products**

A broad range of EDCs presents in cosmetics, household products, drugs and personal care products, among others, exhibited good affinity for proteins involved in breast cancer (Suppl. Table 4. and Suppl. Figure 3). The complexes with the best affinity scores in this group were the perfluorooctane sulfonic acid with the hormone transporter SHBG (Figure 6), and the RARB/AHTN complex (Figure 7).

**A.**

**B.**

Val112A

Leu80A

Asn82A

Met107A

Phe67A

Val105A

Ser42A

Thr60A

Phe56A

Leu171A

Met139A   Ile141A

**Figure 6.** Three-dimensional view of the (A) SHBG/perfluorooctane sulfonic acid complex, (B) showing the binding site and interactions predicted by LigandScout 3.1. The red arrows represent hydrogen-bond acceptor features.

**A.**

**B.**

Ile1272B

Ile1389B

Ile1275B

Leu1271B

Val1311B   Phe1304B

Leu1268B

Ala1234B

Leu1307B

Leu1416B

Phe1230B

Ile1412B

Val1397B

Trp1227B

Leu1400B   Met1408B

**Figure 7.** Three-dimensional view of the (A) RARB/AHTN complex, (B) showing the binding site and interactions predicted by LigandScout 3.1.

Other complexes that also exhibited good affinity scores are presented in Table 3.

**Table 3.** EDCs in everyday products with best affinity scores (<-10.0 kcal/mol) after docking with breast cancer associated proteins.

| Short name | PDB | EDCs | CID | Keywords | Affinity (kcal/mol) |
|---|---|---|---|---|---|
| SHBG | 1F5F | perfluorooctane sulfonic acid | 74483 | Household products | -10.4 |
| RARB | 4DM6 | AHTN | 89440 | Cosmetics | -10.4 |
| GSTP 1 | 3N9J | Emodin | 3220 | Drugs | -10.2 |
| VDR | 1IE9 | 3-(4-methylbenzylidene)camphor | 6434217 | Cosmetics | -10.2 |
| SHBG | 1F5F | 3-(4-methylbenzylidene)camphor | 6434217 | Cosmetics | -10.1 |
| SERPI NB5 | 1WZ9 | Triclocarban | 7547 | Antimicrobial, personal care products, household products | -10.1 |
| CAT | 1DGF | Emodin | 3220 | Drugs | -10.1 |

**2.5.Miscellaneous**

The molecules that exhibited the best affinities in this category were mostly related to combustion, some of them are 3-hydroxy-benzo(a)pyrene, (benzo(a)pyrene and 6-hydroxychrysene (Suppl. Table 5 and Suppl. Figure 4.). The best affinity score, was predicted for the complex CYP1A2/benzo(a)pyrene (Figure 8).



**Figure 8.** Three-dimensional view of the (A) CYP1A2/benzo(a)pyrene complex, (B) showing the binding site and interactions predicted by LigandScout 3.1. The blue arrows represent aromatic ring interactions.

Other complexes with EDCs from different sources also exhibited good affinity scores (Table 4). However, most of them were polycyclic aromatic hydrocarbons (PAHs).

**Table 4.** Miscellaneous EDCs with best affinity scores (<-10.0 kcal/mol) after docking with breast cancer associated proteins.

| Short name | PDB | EDCs | CID | Keywords | Affinity (kcal/mol) |
|---|---|---|---|---|---|
| CYP1A2 | 2HI4 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -13.2 |
| CYP1A2 | 2HI4 | benzanthrone | 6697 | industrial pollutant, combustion | -13.0 |
| CYP1A2 | 2HI4 | 6-hydroxychrysene | 37766 | metabolite, combustion | -12.1 |
| CYP1A2 | 2HI4 | 1-hydroxypyrene | 21387 | metabolite, combustion | -12.0 |
| MYLK4 | 2X4F | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -12.0 |
| RARB | 4DM6 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -12.0 |
| MYLK4 | 2X4F | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.9 |
| SHBG | 1F5F | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.8 |
| CYP1A2 | 2HI4 | 1,9-dimethylphenanthrene | 34454 | environmental pollutant, cigarette | -11.8 |
| CAT | 1DGF | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.8 |
| RARB | 4DM6 | benzanthrone | 6697 | industrial pollutant, combustion | -11.7 |
| CAT | 1DGF | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.6 |
| CAT | 1DGF | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -11.6 |
| CHEK2 | 2W0J | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.5 |
| CHEK2 | 2W0J | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -11.5 |
| MYLK4 | 2X4F | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -11.5 |
| SHBG | 1F5F | 2-hydroxybenzo(a) | 42027 | metabolite, combustion | -11.4 |

| | | | | | |
|---|---|---|---|---|---|
| | | pyrene | | | |
| CYP3A4 | 1TQN | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.4 |
| CHEK2 | 2W0J | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.4 |
| CYP3A4 | 1TQN | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.3 |
| CYP3A4 | 1TQN | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -11.3 |
| CYP2B6 | 3IBD | 6-hydroxychrysene | 37766 | metabolite, combustion | -11.3 |
| SHBG | 1F5F | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.3 |
| PIK3CA | 3HHM | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.2 |
| ADIPOQ | 4DOU | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.2 |
| ADIPOQ | 4DOU | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -11.2 |
| PIK3CA | 3HHM | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.2 |
| ESR2 | 1QKM | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.1 |
| CHEK2 | 2W0J | 6-hydroxychrysene | 37766 | metabolite, combustion | -11.1 |
| ADIPOQ | 4DOU | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.1 |
| CYP1A2 | 2HI4 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.1 |
| CDK2 | 1AQ1 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -11.0 |
| SHBG | 1F5F | 6-hydroxychrysene | 37766 | metabolite, combustion | -11.0 |
| HPGDS | 2VCQ | 2-hydroxybenzo(a) | 42027 | metabolite, combustion | -11.0 |

| | | | | | |
|---|---|---|---|---|---|
| | | pyrene | | | |
| ADIPOQ | 4DOU | 6-hydroxychrysene | 37766 | metabolite, combustion | -11.0 |
| CDK2 | 1AQ1 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -11.0 |
| CDK2 | 1AQ1 | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.9 |
| SRC | 2H8H | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.9 |
| RARG | 2LBD | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.9 |
| MYLK4 | 2X4F | 6-hydroxychrysene | 37766 | metabolite, combustion | -10.9 |
| MYLK4 | 2X4F | benzanthrone | 6697 | industrial pollutant, combustion | -10.9 |
| SHBG | 1F5F | benzanthrone | 6697 | industrial pollutant, combustion | -10.8 |
| NME1 | 1UCN | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.8 |
| RXRG | 2GL8 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.8 |
| SRC | 2H8H | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.8 |
| SRC | 2H8H | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.8 |
| PIK3CA | 3HHM | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.8 |
| CYP2B6 | 3IBD | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.8 |
| RARB | 4DM6 | 1-hydroxypyrene | 21387 | metabolite, combustion | -10.8 |
| RXRB | 1H9U | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.7 |
| RXRB | 1H9U | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.7 |
| AR | 2AM9 | 2-hydroxybenzo(a) | 42027 | metabolite, combustion | -10.7 |

| | | pyrene | | | |
|---|---|---|---|---|---|
| PPARD | 2AWH | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.7 |
| RXRA | 2P1T | HHCB | 91497 | fragrance | -10.7 |
| MYLK4 | 2X4F | 1-hydroxypyrene | 21387 | metabolite, combustion | -10.7 |
| STRADA/ MO25 | 3GNI | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.7 |
| RARB | 4DM6 | 1,9-dimethylphenanthrene | 34454 | environmental pollutant, cigarette | -10.7 |
| HPGDS | 2VCQ | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.6 |
| HPGDS | 2VCQ | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.6 |
| AR | 2AM9 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.6 |
| APOD | 2HZQ | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.6 |
| APOD | 2HZQ | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.6 |
| RXRA | 2P1T | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.6 |
| CAMK2B | 3BHH | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.6 |
| RARB | 4DM6 | 6-hydroxychrysene | 37766 | metabolite, combustion | -10.6 |
| GSTP1 | 3N9J | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.6 |
| CAT | 1DGF | 6-hydroxychrysene | 37766 | metabolite, combustion | -10.6 |
| AR | 2AM9 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.6 |
| CAT | 1DGF | benzanthrone | 6697 | industrial pollutant, combustion | -10.5 |
| RARB | 4DM6 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.5 |

| | | | | | |
|---|---|---|---|---|---|
| NME1 | 1UCN | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.5 |
| PPARD | 2AWH | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.5 |
| APOD | 2HZQ | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.5 |
| STRADA/MO25 | 3GNI | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.5 |
| MAPK1 | 3I60 | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.5 |
| RPS6KB1 | 4L3J | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.5 |
| RPS6KB1 | 4L3J | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.5 |
| ESR2 | 1QKM | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.5 |
| RPS6KB1 | 4L3J | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.5 |
| CYP1A2 | 2HI4 | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.4 |
| NME1 | 1UCN | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.4 |
| PPARD | 2AWH | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.4 |
| RXRG | 2GL8 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.4 |
| RPS6KA1 | 2WNT | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.4 |
| PIK3CG | 3MJW | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.4 |
| GSTP1 | 3N9J | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.4 |
| MET | 1R0P | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.4 |

| | | | | | |
|---|---|---|---|---|---|
| RELA | 2O61 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.4 |
| CAMK2B | 3BHH | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.4 |
| CAMK2B | 3BHH | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.4 |
| NQO1 | 1D4A | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.3 |
| RORA | 1N83 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.3 |
| PGR | 1SQN | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.3 |
| RXRA | 2P1T | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.3 |
| RORC | 3L0L | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.3 |
| PIK3CG | 3MJW | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.3 |
| CXCR4 | 3ODU | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.3 |
| SHBG | 1F5F | 1-hydroxypyrene | 21387 | metabolite, combustion | -10.2 |
| MET | 1R0P | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| MET | 1R0P | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.2 |
| PGR | 1SQN | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.2 |
| PGR | 1SQN | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| NR3C2 | 2AA2 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| AR | 2AM9 | 6-hydroxychrysene | 37766 | metabolite, combustion | -10.2 |

20

| | | | | | |
|---|---|---|---|---|---|
| PPARD | 2AWH | 6-hydroxychrysene | 37766 | metabolite, combustion | -10.2 |
| MSH2 | 2O8B | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.2 |
| RPS6KA1 | 2WNT | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.2 |
| FGFR2 | 3B2T | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.2 |
| ARF-BP1 | 3H1D | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.2 |
| MAPK1 | 3I60 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.2 |
| MAPK1 | 3I60 | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| GSTP1 | 3N9J | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| CHKA | 2CKO | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| RARG | 2LBD | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| HPGDS | 2VCQ | aurin | 5100 | analytical chemistry | -10.2 |
| RPS6KA1 | 2WNT | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| PIK3CA | 3HHM | 6-hydroxychrysene | 37766 | metabolite, combustion | -10.2 |
| MTOR | 4JSN | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.2 |
| PIK3CA | 3HHM | benzanthrone | 6697 | industrial pollutant, combustion | -10.1 |
| CDK2 | 1AQ1 | 6-hydroxychrysene | 37766 | metabolite, combustion | -10.1 |
| CAT | 1DGF | 1-hydroxypyrene | 21387 | metabolite, combustion | -10.1 |
| SHBG | 1F5F | 1,9-dimethylphenant | 34454 | environmental pollutant, cigarette | -10.1 |

| | | | | | |
|---|---|---|---|---|---|
| | | hrene | | | |
| RORA | 1N83 | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.1 |
| NR3C2 | 2AA2 | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.1 |
| NR3C2 | 2AA2 | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.1 |
| ESRRG | 2E2R | 3-monobromobisphenol A | 656688 | metabolite, flame retardants | -10.1 |
| MYLK4 | 2X4F | 1,9-dimethylphenanthrene | 34454 | environmental pollutant, cigarette | -10.1 |
| ESR1 | 3ERT | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.1 |
| RORC | 3L0L | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.1 |
| PPARG | 3LMP | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.1 |
| GSTP1 | 3N9J | benzanthrone | 6697 | industrial pollutant, combustion | -10.1 |
| ADIPOQ | 4DOU | benzanthrone | 6697 | industrial pollutant, combustion | -10.1 |
| MTOR | 4JSN | benzo(a)pyrene | 2336 | combustion, wood, cigarette | -10.1 |
| ESR2 | 1QKM | 3-hydroxy-benzo(a)pyrene | 25890 | combustion | -10.1 |
| ADIPOQ | 4DOU | bis(4-hydroxyphenyl)[(2-phenoxysulfonyl)phenyl]methane | 130780 | analytical chemistry | -10.1 |
| CXCR4 | 3ODU | 2-hydroxybenzo(a)pyrene | 42027 | metabolite, combustion | -10.1 |

### 2.6.BPA/SHBG interaction

The interaction of BPA or its derivatives and breast cancer associated proteins is of special concern, as humans are exposed to these chemicals through contact with different products that contain them, especially through foods that have been in contact with packaging materials that may release these pollutants[16]. Several authors have proposed these chemicals affect the function of multiple organs and increase the risk of breast cancer in mice[17]. In breast cancer, many proteins play a pivotal role in the pathogenesis of this disease. However, SHBG is a small and stable protein with high affinity for estrogens and androgens that has been found in breast tissue and cell lines through immunostaining[18], being the major and specific binding protein for testosterone and estradiol. Besides, decreased circulating levels of this protein have been observed in breast cancer patients possibly indicating higher bioavailable estrogens[19]. These were the main reasons we use to choose it to obtain it and to validate our docking predictions. Therefore, we selected the hormone transporter SHBG[20], as this exhibited a good affinity score in AutoDock Vina (-8.2 kcal/mol), to computationally assess their interactions and conformational changes by CD. Moreover, the data reported in the scientific literature suggest human SHBG may transport some xenostrogens into the plasma and modulate their bioavailability to cell tissues[21], which could disrupt the natural hormones balance.

The conformational analysis performed in LigandScout 3.1[22] suggests that BPA interacts in the binding pocket of SHBG (Figure 9). Most of the interactions of BPA were hydrophobic (Met139A, Leu80A, Val112A), although one residue in the binding site exhibited hydrogen bond

donor and acceptor features (Thr60A), and an aromatic ring interaction was predicted for BPA

and one of the amino acids of the contact residues (Phe67A).



**Figure 9.** Three-dimensional view of the (A) SHBG/ bisphenol A complex, (B) showing the

binding site and interactions predicted by LigandScout 3.1. The green arrows represent hydrogen-bond donor

features, the red arrows show the hydrogen-bond acceptor features, and the blue arrows indicate aromatic ring interactions.

The three-dimensional view of the complex also indicates the position of BPA deep in the

binding site, which can contribute to an elevated affinity. It should be pointed out that

conformational changes should have occurred to allow this docking pose.

**2.7.Protein expression and purification**

Recombinant SHBG was expressed and purified from *E. coli* C41(DE3) cells using Dynabeads His-Tag Isolation and Pulldown. SDS- PAGE electrophoresis gel of the purified protein is presented in Suppl. Figure 5.

### 2.8. Microscale thermophoresis

After FPLC purification a clear separation between the protein and the dye, and a small portion of the total protein was labeled in the collected fractions (75-77) was observed in the spectra. Therefore, this study was used with qualitative purposes, which was enough to evaluate the functionality of the recombinant protein to bind the ligand.

The curve of the MST analysis and the fluorescence data is presented in Suppl. Figure 6. This shows that SHBG has the tendency to bind BPA at around 1µM of BPA, although a saturation point was not reached. This could be the result of a low protein labelling with a high non-labeled protein ratio, which makes more difficult to reach the saturation point as the total protein concentration was high in the sample.

### 2.9. Circular dichroism

The correct folding of the recombinant protein was assessed by CD. According to PDB[23], the secondary structure of SHBG (PDB ID: 1F5F) consist of 4% alpha helix and 40% beta sheets. This correlates with the values obtained by circular dichroism of the SHBG dissolved in PBS at pH 7.4: helix=6.3% and beta sheets=40.6% (strand 1=26.3% and strand 2=14.3%). The results of the secondary structure analysis, according to the DichroWeb[24] software are presented in Figure 10.

**Figure 10.** Changes in the secondary structure of SHBG after incubation with BPA.

At time zero (t=0), no main differences were observed for the contents of helix or strands of the samples of SHBG with BPA $1.5 \times 10^{-5}$ and $4.5 \times 10^{-5}$ M. However, after overnight incubation (t=O/N), an increase in the helix content of the protein was observed, with a percentage increase of more than 20% in both cases. The CD spectra for $1.5 \times 10^{-5}$ and $4.5 \times 10^{-5}$ M of BPA at time zero and overnight are presented in Figure 11. The Dunn's test did not show statistical significant differences between the medians of the SHBG sample and the SHBG/BPA samples in time zero. However, a statistical difference was revealed for the comparison of each sample after overnight incubation with the protein sample, and the SHBG/BPA samples in time zero (Table 5).

**Figure 11.** Processed circular dichroism spectra of SHBG and SHBG incubated with 1.5 x 10$^{-5}$ and 4.5 x 10$^{-5}$ M of BPA at time zero (t=0) and overnight (t=O/N) by DichroWeb[24].

**Table 5.** Results of the statistical analysis.

| Dunn's multiple comparisons test | Mean rank diff, | Significant |
|---|---|---|
| SHBG vs. SHBG/BPA (15µM, t=0) | -26,71 | No |
| SHBG vs. SHBG/BPA (45µM, t=0) | 7,735 | No |
| SHBG vs. SHBG/BPA (15µM, t=O/N) | 101,5 | Yes |
| SHBG vs. SHBG/BPA (45µM, t=O/N) | 78,19 | Yes |
| SHBG/BPA (15µM, t=0) vs. SHBG/BPA (45µM, t=0) | 34,44 | No |
| SHBG/BPA (15µM, t=0) vs. SHBG/BPA (15µM, t=O/N) | 128,2 | Yes |
| SHBG/BPA (15µM, t=0) vs. SHBG/BPA (45µM, t=O/N) | 104,9 | Yes |
| SHBG/BPA (45µM, t=0) vs. SHBG/BPA (15µM, t=O/N) | 93,78 | Yes |
| SHBG/BPA (45µM, t=0) vs. SHBG/BPA (45µM, t=O/N) | 70,45 | Yes |
| SHBG/BPA (15µM, t=O/N) vs. SHBG/BPA (45µM, t=O/N) | -23,33 | No |

3. DISCUSSION

In this work we studied the potential of EDCs from urban sources to target breast cancer proteins using an *in silico* approach. The macromolecules CAT, RARB, SHBG, PGR and PIK3CA presented the highest number of theoretical complexes with xenoestrogens (affinity ≤ - 8.0 kcal/mol). These are pivotal in breast cancer and could be modulating the response to EDCs exposure through metabolic ways. CAT is an antioxidant enzyme that helps to control oxidative stress and DNA damage associated to EDCs exposure and breast cancer development[25]; RARB modulates the proliferation of breast cancer cells by limiting the growth and promoting the apoptosis[26]; SHBG transport steroid hormones through the bloodstream, limiting their free fraction, its binding with xenoestrogens could increase the bioavailable estradiol augmenting the risk of breast cancer[27]; PGR is a well-known marker that together with the ER status is used in the immunohistochemically prognosis of this disease, except for the triple negative subtype, that comprises around 15% of the cases[28]; and PIK3CA has an important role in neoplasia, and aberrations in its pathway or in the gene that codifies it results in an increased risk of cancer[29].

Several of the tested small molecules exhibited high docking affinity in computer simulations and should be prioritized for *in vitro* and *in vivo* assays, in addition some of them showed to be frequent hitters as they act as promiscuous compounds binding different targets[30]. The visual inspection of the docking affinity heat maps (see Supplementary material) indicates that the highest density of protein-ligand pairs with potential to interact between them is presented for dioxins and related molecules. Therefore, this may be the principal source of EDCs interacting

with the metabolic pathways involved in breast cancer. The number of potential targets was followed for the categories: miscellaneous, everyday products, and plastics and other types of polymers, respectively.

The compounds with the highest number of theoretical targets among the breast cancer proteins were the PAHs: 2-hydroxybenzo(a)pyrene, benzo(a)pyrene and 3-hydroxy-benzo(a)pyrene. In the group of plastics and other type of polymers, the most frequent hitter was bisphenol M, followed by the synthetic compound used in the production of thermally stable polyesters and polycarbonates, 4,4'-(octahydro-4,7-methano-5H-inden-5-ylidene) bisphenol, and the styrene trimer, 2,4,6-triphenyl-1-hexene, generated in the decomposition of plastics and released from containers to food[31]. For everyday products, the most promiscuous compound found was the perfluorooctane sulfonic acid. This is interesting, as EDCs can be interacting with many different pathways through protein-ligand interactions making their mechanisms and effects more difficult to understand and control.

The two complexes with the highest affinity scores in the group of dioxins and related molecules were: CAT/1,3,7,8-tetrachlorodibenzo-p-dioxin and CYP1A2/2,3,4,7-tetrachlorodibenzofuran. However, other chemicals in this group also presented very good affinity ($\leq$-9.5 kcal/mol) for CYP1A2 (See suppl. Material Rank_Dioxins), which is in agreement with the scientific literature that indicates this kind of compounds have been found to bind and induce CYP1A2[32]. The eventual binding of 1,3,7,8-tetrachlorodibenzo-p-dioxin to CAT may have an effect in the hydrogen peroxide binding an then in the oxidative stress response.

EDCs from plastics and other types of polymers constitute a special category due to the increased use of these materials in human life, and the annual tendency to augment progressively their already high volumes of production[33]. One of the plasticizers that have received more attention in the last decade is the BPA, a monomer used in polycarbonate plastics and epoxy resins frequently found in food containers, which as a result of restrictive regulations has started to be replaced by other analogues[34]. Surprisingly, some of these derivatives (bisphenol M, bisphenol B, BPAF, dihydroxymethoxychlor olefin and bisphenol A dimethacrylate) are on the top of the complexes with highest docking affinity for breast cancer proteins *in silico* (Table 2), with greater affinity than BPA; therefore we suggest them as priority compounds to be tested against this disease. The two best affinity scores in this group were obtained for bisphenol M in complex with SRC, a protein that may promote the growth of tumor cells and is overexpressed in breast cancer[35]; and for BPAF with ESRRG, an orphan nuclear receptor widely implicated in the transcriptional regulation of energy homeostasis[36] that acts as tumor suppressor in several types of cancers[37]. Interestingly BPAF, has been found to promote breast cancer cell proliferation *in vitro*[38], and bisphenol M exhibited high predicted affinity (<-10.0 kcal/mol) for several proteins related to breast cancer.

A small number of compounds released from household products, cosmetics, drugs and personal care products were found to bind strongly breast cancer proteins *in silico* (<-10.0 kcal/mol, Table 3). Among these, perfluorooctane sulfonic acid, used in the manufacture of plastics, textiles, electronics, and many other industrial products[39]; AHTN found in cosmetics[40]; emodin a medicine that has been found to suppress tumor growth[41]; 3-(4-methylbenzylidene)camphor employed as UV filter in cosmetics[42]; and triclocarban, frequently

utilized in detergents and soaps as antimicrobial agent[43]. Nevertheless, there were many

molecules in this group that presented moderate and weak binding that eventually could have a

role in the homeostasis disruption in relation to the development or progression of this disease.

On the other hand, several of the targeted proteins for these compounds are shared with the top

list for plastics and related molecules, as well as with the proteins most frequently found in

theoretical EDCs-breast cancer protein complexes, some of them are SHBG, RARB, CAT and

vitamin D3 receptor (VDR).

In contrast, a large number of PAHs, derived from combustion, occupied the top ranking of

complexes formed for miscellaneous EDCs. Some of these are the well-known carcinogen

benzo(a)pyrene, benzanthrone, 6-hydroxychrysene and 1-hydroxypyrene. This type of molecules

has been classically associated to breast cancer through genetic damage by DNA adduct

formation[44], however they could also be acting throw protein-ligand interactions. In addition,

other molecules from diverse sources also exhibited high affinity for breast cancer proteins such

as: HHCB, used in fragrances[40]; the chemical indicator aurin[45]; and the flame retardant 3-

monobromobisphenol A[46]; among others (Table 4).

The computer simulations of the docking poses and protein-ligand interaction analysis in the

top complexes of each category showed that the most frequent binding forces were due to

hydrophobic, hydrogen bond donor, hydrogen bond acceptor and aromatic ring features of the

ligands and contact residues in the binding site. The conformational study of the protein-ligand

pair selected for *in vitro* assays, SHBG/BPA, showed that the predicted interacting residues

(Met139A, Thr60A, Phe67A, Leu80A and Val112A), are the same found experimentally on the

binding site of endogenous hormones and xenoestrogens, that binds this protein with high affinity[47]. Therefore, BPA may occupy the pocket for natural estrogens in the body, reducing the fraction of bound estrogen and increasing its bioavailability[48], which is considered a risk factor to develop this disease[18].

The recombinant human SHBG used in our spectroscopic analysis was obtained without any mutation, and according to the MST analysis it was functional, and their folding was the expected, as assessed by the circular dichroism spectra of the native protein without the ligand. The differences in the circular dichroism spectra of SHBG and SHBG with BPA may be the result of both BPA binding and the dimerization of the protein, as has been reported with steroid ligands that bind this protein with high affinity[49]. The main conformational change occurred after BPA binding was an increment of the alpha helix content after overnight incubation, this result has also been observed for the binding of this molecule to other proteins, such as human serum albumin[50]. The Dunn's test showed statistical differences in the spectra for overnight incubation with BPA, but not for the immediate CD recorded after BPA addition (time zero), suggesting that the reaction between BPA and SHBG, may be time-dependent. This is not surprising, as related studies regarding binding assays, used the same physiologic conditions of pH and temperature as in our protocol, as well as an incubation time of at least one hour[48a].

The results discussed in this section showed the plausibility of some EDCs to interact with proteins involved in signaling pathways regarding breast cancer. Therefore further analysis in this field is needed to support regulatory actions, being of special concern the case of the new BPA analogs.

## 4.  CONCLUSIONS

This study presents a virtual screening that helps to understand how endocrine disruptors could be plausible ligands for the breast cancer proteome. This approach provided, important candidates to be evaluated *in vitro* against models of this disease, predicting protein patterns of proteins that are more commonly affected by EDCs. Many of the predicted hits have no scientific reports regarding its experimental evaluation; therefore further studies are required in this field. Computational studies are an important tool that can improve the velocity and efficiency of the evaluations of EDCs overcoming the known limitations regarding the high number of this compounds and diseases associated to them. Several endocrine disruptors have the theoretical capability to bind proteins related to breast cancer, some of them are more promiscuous being able to bind different targets, therefore this are proposed as priority for experimental test. BPA binds SHBG, showing a conformational change of the protein.

## 5.  EXPERIMENTAL SECTION

A four-step approach has been used to identify EDCs with potential to target breast cancer proteins. This includes the selection of the proteins by data mining tools, vHTS, evaluation of *in silico* interactions and experimental validation by spectroscopic methods.

### 5.1.Text mining

Proteomics studies of breast cancer have provided relevant information regarding the identification of proteins of interest in the diagnosis and treatment of this disease[51], even though there is not a consensus list or repository with this information. Therefore, a meta-analysis was performed to identify proteins and genes associated with breast cancer in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), using the text mining tool FABLE (Fast Automated

Biomedical Literature Extraction; http://fable.chop.edu/), employing the key words "breast cancer". The results were ranked according to their number of hits, and a cutoff of ≥100 references related to breast cancer in PubMed was used. This methodology was carried out in order to include the proteins more frequently cited with a role in breast cancer. Some important nuclear receptors and cell cycle targets were also included, as they have been reported to be deregulated in human breast cancer[1a, 52].

## 5.2.High-throughput virtual screening

Molecular docking simulations were carried out to find EDCs with the potential to target breast cancer proteins *in silico*. Calculations were run on Linux RHEL6 for IBM Power, utilizing a System X rack with Power 730 processors. AutoDock Vina[13], an open-source program for molecular docking and virtual screening, was used to assess the binding affinity of each EDC/protein complex, as this software has been largely employed and formally validated for target identification of this kind of molecules, having a high prediction performance when compared to experimental data[53], not only regarding the binding affinity but also the crystallographic binding modes[54]. A total of 305 EDCs from urban sources were downloaded from EDCs DataBank[55] and docked with the selected breast cancer proteins, using the same protocol reported in our previous work for inverse virtual screening[1a]. The crystallographic coordinates of the proteins, with resolution suitable for docking studies (in average, 2.0 Å), were downloaded from Protein Data Bank (PDB)[23] in pdb text format file which were then employed for preprocessing in SYBYL-X 2.0 program package (Tripos, St. Louis, MO). All ions, water molecules and other substructures were removed from the coordinated files and the biopolymer structure preparation tool was used for analyzing and fixing the 3D-structures with default

settings. Optimization of the proteins was also carried out by the same software package employing the Powell method, Kollman united and Kollman all atoms force fields, AMBER charges, dielectric constant 1.0, NB cutoff 8.0, maximum interactions 100 and termination gradient 0.001 kcal/mol. The resultant pdb file was then submitted to AutoDock Tools[56] for preparing the grid parameters and the required pdbqt files for the docking studies. Kollman charges and polar hydrogen atoms were added to the three-dimensional structures of the proteins, the grid was centered in the macromolecule and the size adjusted to include the whole protein surface with a spacing of 0.357 Å. The structures of the EDCs were directly downloaded from EDCs DataBank[55], and used for virtual screening in Autodock Vina[13]. Each ligand/protein pair was docked by triplicate and the best Affinity scores of the single runs were then used to calculate the averages and the results ranked according to these values.

The EDCs were separated according to their source of exposure in four groups: dioxins and related molecules, plastics and other types of polymers, everyday products and miscellaneous. The results ranked and the best protein/ligand complexes of each category were then selected to determine their non-covalent interactions by computer aided simulations. In addition, a hierarchical clustering, which is a powerful tool to blindly explore proteomic data[57], was performed in R (http://www.r-project.org/) for each group, using the "heatmap.2" function of the gplot library[58]. The color key of the heat map, was selected using the RColorBrewer package of R, to present in red the protein-ligand pairs with strong and moderate docking affinity (-15.0 to -8.0 kcal/mol), in white those with weak affinity (-8.0 to -7.0 kcal/mol) and in blue the proteins-ligand pairs that are not likely to interact according to the simulation (-7.0 to 5.0 kcal/mol). As a result, patterns in the behavior of EDCs against breast cancer proteins and vice versa were

identified. The employed affinity cutoff (< -8.0 kcal/mol) was the same used in the protocol of

our previous studies with AutoDock Vina[13], which allowed a good correlation between *in silico*

binding affinity and experimental data[54, 59].

### 5.3. Evaluation of protein-ligand interactions

An *in silico* approach was employed to evaluate the contact residues participating in the

protein-ligand interaction in selected complexes formed between breast cancer related proteins

and EDCs. This was achieved using LigandScout 3.1[22]. The best docking pose of the EDC

resulting from the docking with the target protein by AutoDock Vina[13] was isolated in AutoDock

Tools[56] and merged with the optimized file of the protein structure in pdb format by SYBYL X-

2.0 (Tripos, St. Louis, MO). This file was then used as input in LigandScout, the parameters

utilized for the pharmacophore features and interacting residues were those established by

default in the program.

In order to validate our protocol, a protein-ligand pair, was selected for studying its

interactions *in silico* and *in vitro*. The criteria used to pick the complex that exhibited an Affinity

score near the cutoff (around -8.0 kcal/mol), a common EDC with generalized exposure in the

population and a protein with certain impact in breast cancer.

### 5.4. Experimental validation of the existence of protein-ligand interactions for a predicted
### EDC/protein complex

The protein ligand interaction between bisphenol A (BPA), one of the most common EDCs

used in plastics[60], and the steroid transporter protein sex hormone-binding globulin (SHBG) was

analyzed by LigandScout software[22], using the same protocol described above; and the validation

of the binding and conformational changes of this complex was achieved by spectroscopic

methods[61], employing microscale thermophoresis (MST) and circular dichroism (CD). The

protein was obtained by recombinant DNA technology and BPA (≥99%; 239658-50G) was

purchased from Sigma Aldrich.


### 5.5. Protein expression and purification

The blank plasmid pET15-MHL was transfected into the gene for human SHBG (PDB: 1F5F)

(obtained from Eurofins, Ebersberg), and then harbored in *Escherichia coli* DH5α cells. The

plasmid was purified and transformed into chemically competent *E. coli* C41(DE3). Transformed

cells were plated onto LB agar containing 100 μg/mL of ampicillin, and incubated overnight at

37 °C. A single colony was used to inoculate 100 mL of LB/ampicillin for overnight growth. 20

mL of the starting solution was used to inoculate 400 mL of LB/ampicillin medium. The culture

was incubated at 37 °C (180 rpm) until the $A_{600}$ was 0.6–0.8 at which point protein expression

was induced by the addition of isopropyl 1-thio-β-d-galactopyranoside (IPTG) to a final

concentration of 0.5 mM. After overnight incubation at 20 °C[62], the induced cells were harvested

by centrifugation, the pellet was resuspended in cold PBS buffer and washed twice, resuspended

again in 15 mL of cold lysis buffer (150 mM sodium chloride, 1.0% Triton X-100, 50 mM Tris,

pH 8.0), maintained in agitation 30 min (4°C), and centrifuged (20 min, 12,000 rpm). This pellet

was discarded and the supernatant was placed on ice, and stored at −20 °C until protein

purification   (http://www.abcam.com/index.html?pageconfig=resource&rid=11379).   Magnetic

beads (Dynabeads His-Tag Isolation and Pulldown (Life technologies) were used for protein

purification        according        to        the        protocol        provides        by        the        supplier

(http://tools.lifetechnologies.com/content/sfs/manuals/DynabeadsHisTagIsolationPulldown_man.

pdf). A dialysis procedure was also employed to remove small molecules using a slide-A-Lyzer

Dialysis Cassette, 20K MWCO (Thermo scientific) according to the protocol provided by the

supplier, and a SDS electrophoresis gel was run to check the presence and quality of the protein.

### 5.6. Protein storage

In order to avoid frequent freezing and thawing, the protein sample was divided into aliquots,

stored frozen at -20°C, and kept at physiological pH (PBS buffer pH 7.4).

### 5.7. Microscale Thermophoresis (MST)

In order to evaluate the likelihood of a possible functionality of BPA binding on SHBG, a

qualitative MST analysis was carried out. This method reflects the directed movement of

particles in a microscopic temperature gradient, and enables the analysis of molecular

interactions in solution at microliter scale[63], with low sample consumption[64].

The SHBG protein was labeled using the blue fluorescent dye NT-495-NHS (NanoTemper

Technologies) and incubated for 1 hour at room temperature. In order to separate the free dye

from the protein, a superdex 200 10/300GL column and an AKTA PURE FPLC system (GE

Healthcare) were utilized with PBS buffer pH 7.4 at 0.5 mL/s flow rate. Fractions of 0.25 mL

were collected with a fraction collector F9-R (GE Healthcare). The labeled SHBG was incubated

for 5 min at room temperature with different concentrations of BPA in PBS containing 5%

ethanol as vehicle, testing 1:2 concentrations from 0.03 to 1000 nM (1 µM). The samples (3–5

µL) were loaded into hydrophilic glass capillaries (Monolith NT Capillaries) and the

thermophoresis analysis was performed (LED 40%, IR laser 20%) using a NanoTemper Monolith NT.115 (NanoTemper Technologies) instrument. The capillary used for the MST analysis with BPA and SHBG was the hydrophilic one, as this generated the expected Gaussian curve.

### 5.8. Circular Dichroism

A stock solution consisted of a 30 mM BPA solution in absolute ethanol. The spectra of SHBG (1 μM in Tris pH 7.4) was analyzed to characterize the non-bonded folding state of the recombinant protein, by comparison with the information provided in PDB[23]. The changes in the secondary structure of the protein after BPA binding were accessed by recording the circular dichroism (CD) spectra of SHBG with two concentrations of BPA ($1.5 \times 10^{-5}$ and $4.5 \times 10^{-5}$ M) at time zero and after overnight incubation. The solutions were prepared adding 0.2 and 0.6 μL of the BPA stock solution (30 mM) to 400 μL of SHBG (1 μM in Tris pH 7.4), respectively. The TRIS buffer was used as background and subtracted from all runs. The CD spectra were recorded using the applied photophysics Chriscan, wavelength (nm): 190-350; step: 0.5; time per point (s): 0.5 repeats: 5, temperature: 25°C and auto-subtraction of the background. All the spectra were recorded in both delta A and mdeg units, with 5 repetitions, using a quartz cuvette of 10 mm path length, volume: 0.7 mL, inside: 2 mm; spectral range 190-2500 nm; 4 transparent windows and dimensions 45 mm x 12.5 mm x 12.5 mm, in a nitrogen atmosphere[50]. The data was recorded using the programs Prodata viewer, Chirascan and APLData Converter. The circular dichroism spectra were saved as ASCII files (.kin file format), employing the Pro-data Chriscan software, and utilized as input files in DichroWeb[24] for the secondary structure determination. The parameters used were: file format=free, input units=milidegrees, initial wavelength=190, final

wavelength=350, wavelength step=0.5, lowest datapoint to use in the analysis=190, analysis program=CONTIN, reference set=SMP 180 (Optimized for 190-240 nm), Optional scaling factor=1, Output units=delta epsilon. A statistical analysis of the results of the CD was performed by GraphPad Prism 6.01 (GraphPad Software Inc., San Diego, CA, USA). A non-parametric multiple comparison test Kruskal-Wallis was performed using the raw data of the spectra recorded for SHBG and SHBG/BPA, besides a post-hoc Dunn's multiple comparison test of the row data based on Kruskal-Wallis analysis was also applied to compare the medians of the individual groups. Statistical significance was accepted at $p \leq 0.05$.

ASSOCIATED CONTENT

**Supporting Information**.

Suppl. Table 1. List of proteins and genes associated to breast cancer in the literature according to FABLE (Accessed: 12 dic 2012).

Suppl. Table 2. Docking affinity scores for dioxins and related molecules with breast cancer associated proteins.

Suppl. Table 3. Docking affinity scores for EDCs from plastics and other polymers with breast cancer associated proteins.

Suppl. Table 4. Docking affinity scores for EDCs from everyday products with breast cancer associated proteins.

Suppl. Table 5. Docking affinity scores for miscellaneous EDCs with breast cancer associated proteins.

Suppl. Figure 1. Cluster heat map of the docking affinity scores obtained for EDCs in the group of dioxins and related molecules (columns) and breast cancer proteins (rows).

Suppl. Figure 2. Cluster heat map of the docking affinity scores obtained for EDCs in the group of plastics and other types of polymers(columns) and breast cancer proteins (rows).

Suppl. Figure 3. Cluster heat map of the docking affinity scores obtained for EDCs in the group of Everyday Products (columns) and breast cancer proteins (rows).

Suppl. Figure 4. Cluster heat map of the docking affinity scores obtained for EDCs in the group of Miscellaneous (columns) and breast cancer proteins (rows).

Suppl. Figure 5. SDS-PAGE of the purified SHBG protein.

Suppl. Figure 6. Microscale thermophoresis (MST) study of the protein-ligand interaction of fluorescently labeled SHBG and BPA.

AUTHOR INFORMATION

Corresponding Author

*J O-V: e-mail: joliverov@unicartagena.edu.co, phone: +57 5 6698179.

*GB: e-mail: gb453@cam.ac.uk, phone: +44 0 1223336305.

Author Contributions

ABBREVIATIONS

ADIPOQ, adiponectin; APOD, apolipoprotein D; BPA, bisphenol A; BPAF, bisphenol AF; BRCA1, breast cancer type 1 susceptibility protein; BRCA2, breast cancer type 2 susceptibility protein; CAT, catalase; CD, circular dichroism; CDK2, cyclin-dependent kinase 2; CHEK2, serine/threonine-protein kinase Chk2; CYP1A2, cytochrome P450 1A2; CYP2B6, cytochrome P450 2B6; CYP3A4, cytochrome P450 3A4; EDCs, endocrine disrupting chemicals; EPA, Environmental Protection Agency; ESR1, estrogen receptor; ESRRG, estrogen-related receptor gamma; FABLE, fast automated biomedical literature extraction; GSTP1, glutathione S-transferase P; HBA1, hemoglobin subunit alpha; HER-2, human epidermal growth factor receptor 2; HPGDS , hematopoietic prostaglandin D synthase; HTS, high-throughput screening; IPTG, isopropyl 1-thio-β-d-galactopyranoside MET , hepatocyte growth factor receptor; MMP9,

matrix metalloproteinase-9; MST, microscale thermophoresis; MYLK4, myosin light chain

kinase family member 4; NME1, nucleoside diphosphate kinase A; NP2, nitrophorin-2; NQO1,

NAD(P)H dehydrogenase [quinone] 1; NR3C1, glucocorticoid receptor; OH-PCBs Hydroxylated

polychlorinated biphenyls; O/N, overnight; PAHs, polycyclic aromatic hydrocarbons; PCBs,

polychlorinated biphenyls; PDB, Protein Data Bank; PGR, progesterone receptor; PIK3CA,

phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; RARB, retinoic

acid receptor beta; RXRG , retinoic acid receptor RXR-gamma; RORA, nuclear receptor ROR-

alpha; RORC, nuclear receptor ROR-gamma; RPS6KB1, ribosomal protein S6 kinase beta-1;

SHBG, sex hormone-binding globulin; SRC , proto-oncogene tyrosine-protein kinase Src; VDR,

vitamin D3 receptor; vHTS, virtual high-throughput screening; WHO, World Health

Organization.

REFERENCES

1.      (a) Lee, H.-R.; Hwang, K.-A.; Nam, K.-H.; Kim, H.-C.; Choi, K.-C., Progression of
breast cancer cells was enhanced by endocrine-disrupting chemicals, triclosan and octylphenol,
via an estrogen receptor-dependent signaling pathway in cellular and mouse xenograft models.
*Chem. Res. Toxicol.* **2014,** *27* (5), 834-842; (b) Knower, K. C.; To, S. Q.; Leung, Y.-K.; Ho, S.-
M.; Clyne, C. D., Endocrine disruption of the epigenome: a breast cancer link. *Endocr. Relat.
Cancer* **2014,** *21* (2), T33-T55; (c) Martos, S. N.; Tang, W.-y.; Wang, Z., Elusive inheritance:
Transgenerational effects and epigenetic inheritance in human environmental disease. *Prog.
Biophys. Mol. Biol.* **2015,** *118* (1–2), 44-54; (d) Anway, M. D.; Cupp, A. S.; Uzumcu, M.;
Skinner, M. K., Epigenetic Transgenerational Actions of Endocrine Disruptors and Male
Fertility. *Science* **2005,** *308* (5727), 1466-1469; (e) Izzotti, A.; Kanitz, S.; D'Agostini, F.;
Camoirano, A.; De Flora, S., Formation of adducts by bisphenol A, an endocrine disruptor, in
DNA in vitro and in liver and mammary tissue of mice. *Mutat. Res.* **2009,** *679* (1–2), 28-32.
2.      Futran Fuhrman, V.; Tal, A.; Arnon, S., Why endocrine disrupting chemicals (EDCs)
challenge traditional risk assessment and how to respond. *J. Hazard. Mater.* **2015,** *286* (0), 589-
611.
3.      Teitelbaum, S. L.; Belpoggi, F.; Reinlib, L., Advancing research on endocrine disrupting
chemicals in breast cancer: Expert panel recommendations. *Reprod. Toxicol.* **2015,** *54* (0), 141-
147.
4.      Ihara, M.; Ihara, M. O.; Kumar, V.; Narumiya, M.; Hanamoto, S.; Nakada, N.;
Yamashita, N.; Miyagawa, S.; Iguchi, T.; Tanaka, H., Co-occurrence of Estrogenic and

Antiestrogenic Activities in Wastewater: Quantitative Evaluation of Balance by in Vitro ERα Reporter Gene Assay and Chemical Analysis. *Environ. Sci. Technol.* **2014,** *48* (11), 6366-6373.

5.      (a) Wu, R. S. S.; Zhou, B. S.; Randall, D. J.; Woo, N. Y. S.; Lam, P. K. S., Aquatic Hypoxia Is an Endocrine Disruptor and Impairs Fish Reproduction. *Environ. Sci. Technol.* **2003,** *37* (6), 1137-1141; (b) Kanno, J.; Kato, H.; Iwata, T.; Inoue, T., Phytoestrogen-Low Diet for Endocrine Disruptor Studies. *J. Agric. Food Chem.* **2002,** *50* (13), 3883-3885; (c) Benotti, M. J.; Trenholm, R. A.; Vanderford, B. J.; Holady, J. C.; Stanford, B. D.; Snyder, S. A., Pharmaceuticals and Endocrine Disrupting Compounds in U.S. Drinking Water. *Environ. Sci. Technol.* **2009,** *43* (3), 597-603; (d) Westerhoff, P.; Yoon, Y.; Snyder, S.; Wert, E., Fate of Endocrine-Disruptor, Pharmaceutical, and Personal Care Product Chemicals during Simulated Drinking Water Treatment Processes. *Environ. Sci. Technol.* **2005,** *39* (17), 6649-6663; (e) Guenther, K.; Heinke, V.; Thiele, B.; Kleist, E.; Prast, H.; Raecker, T., Endocrine Disrupting Nonylphenols Are Ubiquitous in Food. *Environ. Sci. Technol.* **2002,** *36* (8), 1676-1680; (f) Park, B. J.; Palace, V.; Wautier, K.; Gemmill, B.; Tomy, G., Thyroid Axis Disruption in Juvenile Brown Trout (Salmo trutta) Exposed to the Flame Retardant β-Tetrabromoethylcyclohexane (β-TBECH) via the Diet. *Environ. Sci. Technol.* **2011,** *45* (18), 7923-7927.

6.      (a) Hauser, R.; Skakkebaek, N. E.; Hass, U.; Toppari, J.; Juul, A.; Andersson, A. M.; Kortenkamp, A.; Heindel, J. J.; Trasande, L., Male Reproductive Disorders, Diseases, and Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union. *J. Clin. Endocrinol. Metab.* **2015,** *100* (4), 1267-1277; (b) Bellanger, M.; Demeneix, B.; Grandjean, P.; Zoeller, R. T.; Trasande, L., Neurobehavioral Deficits, Diseases, and Associated Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union. *J. Clin. Endocrinol. Metab.* **2015,** *100* (4), 1256-1266; (c) Bedia, C.; Dalmau, N.; Jaumot, J.; Tauler, R., Phenotypic malignant changes and untargeted lipidomic analysis of long-term exposed prostate cancer cells to endocrine disruptors. *Environ. Res.* **2015,** *140* (0), 18-31; (d) Prins, G. S., Endocrine disruptors and prostate cancer risk. *Endocr. Relat. Cancer* **2008,** *15* (3), 649-656.

7.      Brody, J. T., *Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case-control study*. National Network on Environments and Women's Health: 2012.

8.      Miyagawa, S.; Lange, A.; Hirakawa, I.; Tohyama, S.; Ogino, Y.; Mizutani, T.; Kagami, Y.; Kusano, T.; Ihara, M.; Tanaka, H.; Tatarazako, N.; Ohta, Y.; Katsu, Y.; Tyler, C. R.; Iguchi, T., Differing Species Responsiveness of Estrogenic Contaminants in Fish Is Conferred by the Ligand Binding Domain of the Estrogen Receptor. *Environ. Sci. Technol.* **2014,** *48* (9), 5254-5263.

9.      Hulka, B. S.; Moorman, P. G., Breast cancer: hormones and other risk factors. *Maturitas* **2001,** *38* (1), 103-113.

10.      Rotroff, D. M.; Martin, M. T.; Dix, D. J.; Filer, D. L.; Houck, K. A.; Knudsen, T. B.; Sipes, N. S.; Reif, D. M.; Xia, M.; Huang, R.; Judson, R. S., Predictive Endocrine Testing in the 21st Century Using in Vitro Assays of Estrogen Receptor Signaling Responses. *Environ. Sci. Technol.* **2014,** *48* (15), 8706-8716.

11.      Erickson, B. E., EPA RETOOLS ENDOCRINE PROGRAM. *Chem. Eng. News* **2013,** *91* (11), 30-32.

12.      Kemsley, J., Rethinking breast cancer toxicology. *Chem. Eng. News* **2010,** *88* (10), 40-41.

44

13.    Trott, O.; Olson, A. J., AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **2010,** *31* (2), 455-461.

14.    Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K. P.; Kuhn, M.; Bork, P.; Jensen, L. J.; von Mering, C., STRING v10: protein–protein interaction networks, integrated over the tree of life. *Nucleic Acids Res.* **2015,** *43* (D1), D447-D452.

15.    Song, S.; Ruan, T.; Wang, T.; Liu, R.; Jiang, G., Distribution and Preliminary Exposure Assessment of Bisphenol AF (BPAF) in Various Environmental Matrices around a Manufacturing Plant in China. *Environ. Sci. Technol.* **2012,** *46* (24), 13136-13143.

16.    Yang, Y.; Yu, J.; Yin, J.; Shao, B.; Zhang, J., Molecularly Imprinted Solid-Phase Extraction for Selective Extraction of Bisphenol Analogues in Beverages and Canned Food. *J. Agric. Food. Chem.* **2014,** *62* (46), 11130-11137.

17.    (a) Lozada, K. W.; Keri, R. A., Bisphenol A increases mammary cancer risk in two distinct mouse models of breast cancer. *Biol. Reprod.* **2011,** *85* (3), 490-497; (b) Starovoytov, O. N.; Liu, Y.; Tan, L.; Yang, S., Effects of the Hydroxyl Group on Phenyl Based Ligand/ERRγ Protein Binding. *Chem. Res. Toxicol.* **2014,** *27* (8), 1371-1379.

18.    Moore, K. H.; Bertram, K. A.; Gomez, R. R.; Styner, M. J.; Matej, L. A., Sex hormone binding globulin mRNA in human breast cancer: Detection in cell lines and tumor samples. *J. Steroid Biochem. Mol. Biol.* **1996,** *59* (3–4), 297-304.

19.    Naik S L, D.; Hedau, S.; Bahadur, A.; Saha, R.; Kaur, S.; Ray, A., Sex hormone binding globulin in breast cancer. *Indian J Clin Biochem* **2008,** *23* (3), 250-254.

20.    Miguel-Queralt, S.; Hammond, G. L., Sex Hormone-Binding Globulin in Fish Gills Is a Portal for Sex Steroids Breached by Xenobiotics. *Endocrinology* **2008,** *149* (9), 4269-4275.

21.    Cherkasov, A.; Shi, Z.; Fallahi, M.; Hammond, G. L., Successful in Silico Discovery of Novel Nonsteroidal Ligands for Human Sex Hormone Binding Globulin. *J. Med. Chem.* **2005,** *48* (9), 3203-3213.

22.    Wolber, G.; Langer, T., LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters. *J. Chem. Inf. Model.* **2005,** *45* (1), 160-169.

23.    Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E., The Protein Data Bank. *Nucleic Acids Res.* **2000,** *28* (1), 235-242.

24.    Whitmore, L.; Wallace, B. A., DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. *Nucleic Acids Res.* **2004,** *32* (Web Server issue), W668-W673.

25.    Oakley, G. G.; Devanaboyina, U.-s.; Robertson, L. W.; Gupta, R. C., Oxidative DNA Damage Induced by Activation of Polychlorinated Biphenyls (PCBs): Implications for PCB-Induced Oxidative Stress in Breast Cancer. *Chem. Res. Toxicol.* **1996,** *9* (8), 1285-1292.

26.    Seewaldt, V. L.; Johnson, B. S.; Parker, M. B.; Collins, S. J.; Swisshelm, K., Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. *Cell Growth Differ.* **1995,** *6* (9), 1077-1088.

27.    (a) Bruning, P. F.; Bonfrèr, J. M.; Hart, A. A., Non-protein bound oestradiol, sex hormone binding globulin, breast cancer and breast cancer risk. *Br. J. Cancer* **1985,** *51* (4), 479-484; (b) Moore, J. W.; Key, T. J.; Bulbrook, R. D.; Clark, G. M.; Allen, D. S.; Wang, D. Y.; Pike, M. C., Sex hormone binding globulin and risk factors for breast cancer in a population of

normal women who had never used exogenous sex hormones. *Br. J. Cancer* **1987,** *56* (5), 661-666.

28.    Bauer, K. R.; Brown, M.; Cress, R. D.; Parise, C. A.; Caggiano, V., Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. *Cancer* **2007,** *109* (9), 1721-1728.

29.    (a) Brachmann, S. M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S.-M., Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. *Proc. Natl. Acad. Sci. U.S.A.* **2009,** *106* (52), 22299-22304; (b) Kalinsky, K.; Jacks, L. M.; Heguy, A.; Patil, S.; Drobnjak, M.; Bhanot, U. K.; Hedvat, C. V.; Traina, T. A.; Solit, D.; Gerald, W.; Moynahan, M. E., PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. *Clin. Cancer Res.* **2009,** *15* (16), 5049-5059.

30.    Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E.-M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjögren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von der Saal, W.; Zimmermann, G.; Schneider, G., Development of a Virtual Screening Method for Identification of "Frequent Hitters" in Compound Libraries. *J. Med. Chem.* **2002,** *45* (1), 137-142.

31.    Ohyama, K.-I.; Satoh, K.; Sakamoto, Y.; Ogata, A.; Nagai, F., Effects of Prenatal Exposure to Styrene Trimers on Genital Organs and Hormones in Male Rats. *Exp. Biol. Med.* **2007,** *232* (2), 301-308.

32.    Staskal, D. F.; Diliberto, J. J.; DeVito, M. J.; Birnbaum, L. S., Inhibition of Human and Rat CYP1A2 by TCDD and Dioxin-like Chemicals. *Toxicol. Sci.* **2005,** *84* (2), 225-231.

33.    Thompson, R. C.; Moore, C. J.; vom Saal, F. S.; Swan, S. H., Plastics, the environment and human health: current consensus and future trends. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* **2009,** *364* (1526), 2153-2166.

34.    Deceuninck, Y.; Bichon, E.; Marchand, P.; Boquien, C.-Y.; Legrand, A.; Boscher, C.; Antignac, J.; Le Bizec, B., Determination of bisphenol A and related substitutes/analogues in human breast milk using gas chromatography-tandem mass spectrometry. *Anal. Bioanal. Chem.* **2015,** *407* (9), 2485-2497.

35.    Biscardi, J. S.; Ishizawar, R. C.; Silva, C. M.; Parsons, S. J., Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer. *Breast Cancer Res.* **2000,** *2* (3), 203-210.

36.    Madhavan, S.; Gusev, Y.; Singh, S.; Riggins, R. B., ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer. *J. Exp. Clin. Cancer Res.* **2015,** *34* (1).

37.    Su, N.; Qiu, H.; Chen, Y.; Yang, T.; Yan, Q.; Wan, X., miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. *Oncol. Rep.* **2013,** *29* (6), 2297-2302.

38.    Fernandez, M. F.; Arrebola, J. P.; Taoufiki, J.; Navalón, A.; Ballesteros, O.; Pulgar, R.; Vilchez, J. L.; Olea, N., Bisphenol-A and chlorinated derivatives in adipose tissue of women. *Reprod. Toxicol.* **2007,** *24* (2), 259-264.

39.    Eriksen, K. T.; Sørensen, M.; McLaughlin, J. K.; Lipworth, L.; Tjønneland, A.; Overvad, K.; Raaschou-Nielsen, O., Perfluorooctanoate and Perfluorooctanesulfonate Plasma Levels and Risk of Cancer in the General Danish Population. *J. Natl. Cancer Inst.* **2009,** *101* (8), 605-609.

40.    Seinen, W.; Lemmen, J. G.; Pieters, R. H. H.; Verbruggen, E. M. J.; van der Burg, B., AHTN and HHCB show weak estrogenic — but no uterotrophic activity. *Toxicol. Lett.* **1999,** *111* (1–2), 161-168.

41.    Huang, Z.; Chen, G.; Shi, P., Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway. *Arch. Pharm. Res.* **2008,** *31* (6), 742-748.

42.    Schlumpf, M.; Jarry, H.; Wuttke, W.; Ma, R.; Lichtensteiger, W., Estrogenic activity and estrogen receptor β binding of the UV filter 3-benzylidene camphor: Comparison with 4-methylbenzylidene camphor. *Toxicology* **2004,** *199* (2), 109-120.

43.    Tarnow, P.; Tralau, T.; Hunecke, D.; Luch, A., Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells. *Toxicol. In Vitro* **2013,** *27* (5), 1467-1475.

44.    Rundle, A.; Tang, D.; Hibshoosh, H.; Estabrook, A.; Schnabel, F.; Cao, W.; Grumet, S.; Perera, F. P., The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. *Carcinogenesis* **2000,** *21* (7), 1281-1289.

45.    Lippold, T. G.; Kohli, N.; Endo, P. D.; Hui, H. K.; Lin, S.-M., Indicator dye for use in the detection of presence of oxidizing agents. Google Patents: 2005.

46.    Meerts, I. A.; Letcher, R. J.; Hoving, S.; Marsh, G.; Bergman, A.; Lemmen, J. G.; van der Burg, B.; Brouwer, A., In vitro estrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds. *Environ. Health Perspect.* **2001,** *109* (4), 399-407.

47.    Grishkovskaya, I.; Avvakumov, G. V.; Hammond, G. L.; Catalano, M. G.; Muller, Y. A., Steroid Ligands Bind Human Sex Hormone-binding Globulin in Specific Orientations and Produce Distinct Changes in Protein Conformation. *J. Biol. Chem.* **2002,** *277* (35), 32086-32093.

48.    (a) Déchaud, H.; Ravard, C.; Claustrat, F.; de la Perrière, A. B.; Pugeat, M., Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG)1. *Steroids* **1999,** *64* (5), 328-334; (b) Gale, W. L.; Patiño, R.; Maule, A. G., Interaction of xenobiotics with estrogen receptors α and β and a putative plasma sex hormone-binding globulin from channel catfish (Ictalurus punctatus). *Gen. Comp. Endocrinol.* **2004,** *136* (3), 338-345.

49.    Hildebrand, C.; Bocchinfuso, W. P.; Dales, D.; Hammond, G. L., Resolution of the steroid-binding and dimerization domains of human sex hormone-binding globulin by expression in Escherichia coli. *Biochemistry* **1995,** *34* (10), 3231-3238.

50.    Xie, X.; Wang, X.; Xu, X.; Sun, H.; Chen, X., Investigation of the interaction between endocrine disruptor bisphenol A and human serum albumin. *Chemosphere* **2010,** *80* (9), 1075-1080.

51.    Hondermarck, H.; Tastet, C.; El Yazidi-Belkoura, I.; Toillon, R.-A.; Le Bourhis, X., Proteomics of Breast Cancer: The Quest for Markers and Therapeutic Targets. *J. Proteome Res.* **2008,** *7* (4), 1403-1411.

52.    Yu, K.; Toral-Barza, L.; Discafani, C.; Zhang, W. G.; Skotnicki, J.; Frost, P.; Gibbons, J. J., mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. *Endocr. Relat. Cancer.* **2001,** *8* (3), 249-258.

53.    Kolšek, K.; Mavri, J.; Sollner Dolenc, M.; Gobec, S.; Turk, S., Endocrine Disruptome—An Open Source Prediction Tool for Assessing Endocrine Disruption Potential through Nuclear Receptor Binding. *J. Chem. Inf. Model.* **2014,** *54* (4), 1254-1267.

54.    Montes-Grajales, D.; Olivero-Verbel, J., Computer-aided identification of novel protein targets of bisphenol A. *Toxicol. Lett.* **2013,** *222* (3), 312-320.

55.    Montes-Grajales, D.; Olivero-Verbel, J., EDCs DataBank: 3D-Structure database of endocrine disrupting chemicals. *Toxicology* **2015,** *327* (0), 87-94.

56.    Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J. Comput. Chem.* **2009,** *30* (16), 2785-2791.

57.    Meunier, B.; Dumas, E.; Piec, I.; Bechet, D.; Hebraud, M.; Hocquette, J.-F., Assessment of hierarchical clustering methodologies for proteomic data mining. *J. Proteome Res.* **2007,** *6* (1), 358-366.

58.    Warnes, G. R.; Bolker, B.; Bonebakker, L.; Gentleman, R.; Huber, W.; Liaw, A.; Lumley, T.; Maechler, M.; Magnusson, A.; Moeller, S., gplots: Various R programming tools for plotting data. *R package version* **2009,** *2* (4).

59.    Maldonado-Rojas, W.; Olivero-Verbel, J., Food-related compounds that modulate expression of inducible nitric oxide synthase may act as its inhibitors. *Molecules* **2012,** *17* (7), 8118-8135.

60.    Lorber, M.; Schecter, A.; Paepke, O.; Shropshire, W.; Christensen, K.; Birnbaum, L., Exposure assessment of adult intake of bisphenol A (BPA) with emphasis on canned food dietary exposures. *Environ. Int.* **2015,** *77*, 55-62.

61.    Fang, X.; Cao, S.; Liu, R., Interaction of Bisphenol A with Bovine Hemoglobin Using Spectroscopic and Molecular Modeling Methods. *Appl. Spectrosc.* **2011,** *65* (11), 1250-1253.

62.    Montgomery, C.; Pei, Z.; Watkins, P. A.; Miziorko, H. M., Identification and Characterization of an Extramitochondrial Human 3-Hydroxy-3-methylglutaryl-CoA Lyase. *J. Biol. Chem.* **2012,** *287* (40), 33227-33236.

63.    Rimmerman, N.; Ben-Hail, D.; Porat, Z.; Juknat, A.; Kozela, E.; Daniels, M. P.; Connelly, P. S.; Leishman, E.; Bradshaw, H. B.; Shoshan-Barmatz, V.; Vogel, Z., Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. *Cell. Death Dis.* **2013,** *4*, e949.

64.    Seidel, S. A. I.; Dijkman, P. M.; Lea, W. A.; van den Bogaart, G.; Jerabek-Willemsen, M.; Lazic, A.; Joseph, J. S.; Srinivasan, P.; Baaske, P.; Simeonov, A.; Katrich, I.; Melo, F. A.; Ladbury, J. E.; Schreiber, G.; Watts, A.; Braun, D.; Duhr, S., Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. *Methods* **2013,** *59* (3), 301-315.

**Websites**

US National Library of Medicine. PubMed. http://www.ncbi.nlm.nih.gov/pubmed/ (accessed Jun 22, 2015).

Fast Automated Biomedical Literature Extraction. FABLE. http://fable.chop.edu/ (accessed Jun 22, 2015).

ABCAM.                Sample                preparation                protocols.

http://www.abcam.com/index.html?pageconfig=resource&rid=11379 (accessed Jun 22, 2015).

Life        Technologies.        Dynabeads        His-Tag        Isolation        and        Pulldown.

http://tools.lifetechnologies.com/content/sfs/manuals/DynabeadsHisTagIsolationPulldown_man.

pdf (accessed Jun 22, 2015).

**Software**

SYBYL-X 2.0 program package. Tripos, St. Louis, MO.

AutoDock Tools (http://autodock.scripps.edu/resources/adt).

R, version 3.1.2; A language and environment for statistical computing. R Foundation for

Statistical Computing, Vienna, Austria. 2012; ISBN 3-900051-07-0 (accessed Jun 22, 2015).

Table of contents graphic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60